Podophyllotoxin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Topical/Cutaneous Condyloma acuminata affecting the external genitals As 0.15% cream or 0.5 % solution: Apply bid for 3 days; if needed, repeat at weekly intervals for 4 or 5 weeks treatment. Anogenital warts As 0.5% gel: Apply bid for 3 days; if needed, repeat at weekly intervals for 4 or 5 weeks treatment.
Dosage Details
Topical/Cutaneous
Anogenital warts
Adult: As 0.5% gel: Apply bid for 3 days; if needed, repeat at weekly intervals for 4 or 5 weeks treatment. Max: 0.5 g daily or ≤10 cm2 of wart tissue.
Child: >12 years Same as adult dose.

Topical/Cutaneous
Condyloma acuminata
Adult: For cases affecting the external genitals: As 0.15% cream or 0.5 % solution: Apply bid for 3 days; if needed, repeat at weekly intervals for 4 weeks. Max (0.5% solution): 0.5 mL daily or ≤10 cm2 of wart tissue.
Contraindications
Broken skin. Children <12 years. Pregnancy and lactation.
Special Precautions
Children.
Adverse Reactions
Significant: Application site reactions (e.g. irritation, inflammation, burning sensation, erythema, pruritus, bleeding), erosion.
GI disorders: Vomiting.
Nervous system disorders: Headache, dizziness.
Psychiatric disorders: Insomnia.
Renal and urinary disorders: Haematuria.
Reproductive system and breast disorders: Balanoposthitis.
Vascular disorders: Bleeding.
Patient Counseling Information
Avoid use of occlusive dressing or wrappings. Avoid contact with eyes and mucous membranes (e.g. genital area). Topical gel and solution is flammable, avoid exposure to excessive heat and flame. Refrain from engaging in sexual activity on days during treatment.
Overdosage
Symptoms: Nausea, vomiting, abdominal pain, diarrhoea, hepatotoxicity, renal failure, thrombocytopenia, leucopenia; delayed CNS-related effects including acute psychotic reactions, hallucinations, confusion, dizziness, stupor, ataxia, hypotonia, seizures, coma; delayed peripheral neuropathies resulting to paraesthesias, reduced reflexes, muscle weakness, tachycardia, apnoea, orthostatic hypotension, paralytic ileus, urinary retention. Management: Symptomatic and supportive treatment. Wash off from the application area.
Action
Description: Podophyllotoxin is a keratolytic with an antimitotic action. It binds to the microtubule protein of the mitotic spindle thereby inhibiting metaphase and leading to cell death and necrosis of wart tissue.
Pharmacokinetics:
Absorption: Absorbed through the skin or mucous membranes. Time to peak plasma concentration: 1-2 hour.
Excretion: Plasma elimination half-life: 1- 4.5 hour.
Chemical Structure

Chemical Structure Image
Podophyllotoxin

Source: National Center for Biotechnology Information. PubChem Database. Podofilox, CID=10607, https://pubchem.ncbi.nlm.nih.gov/compound/Podofilox (accessed on Jan. 23, 2020)

Storage
Store between 20-25°C. Protect from excessive heat and open flames.
ATC Classification
D06BB04 - podophyllotoxin ; Belongs to the class of topical antivirals used in the treatment of dermatological diseases.
References
Anon. Podofilox. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 23/11/2017.

Anon. Podofilox. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 23/11/2017.

Buckingham R (ed). Podophyllum. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/11/2017.

Condylox Gel (Actavis Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/11/2017.

Joint Formulary Committee. Podophyllotoxin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/11/2017.

Podofilox Solution (Actavis Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/11/2017.

Disclaimer: This information is independently developed by MIMS based on Podophyllotoxin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in